News and Trends 12 Jul 2022 AI being used to perform molecular analysis of biopsies from bowel disease patients Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […] July 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […] July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 U.S. biotech financing drops 46% in Q1 compared to 2021 Venture financing deal value for U.S.-headquartered biotech companies dipped by 46% in Q1 2022 compared to Q1 2021, according to analysis from GlobalData. The data and analytics company said the decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, business fundamentals […] July 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 ARCH Venture Partners launches $3B fund for biotech companies ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. The new fund follows the January 2021 announcement of the $1.941 billion ARCH Venture Fund XI. “All the fundamental innovations in biotechnology are accelerating, with huge promise […] June 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 Eye inflammation leads to FDA partial clinical hold on Nuvation Bio solid tumor study U.S. biopharma company Nuvation Bio Inc. says the Food and Drug Administration (FDA) has placed a partial clinical hold on the company’s phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The company’s Phase 1 trial began enrolling patients in […] June 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 Fermentation facility opens its doors in Wisconsin A new fermentation facility producing food ingredients and cultures, bacterial cultures, and probiotics has been opened in Franksville, Wisc., by Cultures Supporting Life (CSL). The ingredients, cultures and probiotics produced will be used in dairy, food, dietary supplements, pharma, and agriculture. Kyle Griffiths, vice president of sales and marketing said: “The new production facilities located […] June 27, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2022 The biggest US biotech investments in May 2022 The DNA sequencing newcomer Ultima Genomics won the crown for the biggest U.S private biotech investment in May 2022. Other top fundraising firms are developing gene and cell therapies in addition to cultured leather and omics-based diagnostics. The headliner private biotech investment in the US in May 2022 went to the Californian firm Ultima Genomics. […] June 27, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Stramsen Biotech to look at 11 plant-based drug candidates Houston-based biotechnology firm Stramsen Biotech Inc. has announced 11 drug candidates for clinical development. Kefas Mugittu, co-CEO, made the announcement of the plant-based medical candidates. The company said the drugs are safe, effective and currently in use in different countries. The drug candidates are: SBX 1052, which controls/prevents enlargement of the prostate glands; SBX1968, which […] June 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Antheia gets funding to build biomanufacturing plant Antheia, a U.S. synthetic biology company enabling next-generation plant-inspired medicines, has announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank. The company also unveiled plans to construct a new pilot scale biomanufacturing facility. The financing will support Antheia’s expansion with a 14,700 square-foot pilot plant located next to Antheia’s […] June 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Gemelli Biotech to work on gastrointestinal diseases with new $19M funding U.S.-headquartered Gemelli Biotech Corp, which focuses on precision diagnostics for gastrointestinal (GI) diseases, has completed a $19 million series A finance round. Blue Ox Healthcare Partners, a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 US Toddlers and children to receive Covid-19 vaccine after emergency approval granted Emergency authorization was granted for the use of the Pfizer-BioNTech Covid-19 vaccines on children from six months old to under five years of age. The US Food and Drug Administration made the authorization on Friday (June 17). All children ages 6 months and up are now eligible to receive the COVID-19 vaccine, following the US […] June 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email